title: A preliminary pilot study of treatment of thrombophilia and hypofibrinolysis and amelioration of the pain of osteonecrosis of the jaws.
abstract: OBJECTIVE
  In a preliminary pilot study of 30 treatments in 26 patients with osteonecrosis of the jaws and chronic disabling facial pain, our specific aim was to determine whether, to what degree, and how safely therapy of hypofibrinolysis and thrombophilia would ameliorate the chronic pain associated with osteonecrosis of the mandible and maxilla.
  
  
  METHODS
  Thrombophilia was treated with Coumadin (DuPont) in 10 patients; hypofibrinolysis was treated with Winstrol (Sanofi-Winthrop) in 20 patients, including 4 who had mixed thrombophilia and hypofibrinolysis and had previously been treated with Coumadin. The initial treatment period was targeted to be 4 months. Each patient was asked to keep a daily written pain-relief numeric rating score and side-effects diary and to provide a summary pain-relief numeric rating score and side effects compilation for the total treatment period.
  
  
  RESULTS
  There were 4 men and 22 women in the study group; their mean age was 49 +/- 11 years. The mean onset of their osteonecrosis pain was at age 45 +/- 12 years, and the mean duration of their facial pain prior to therapy was 4.5 +/- 4.2 years. Ten patients had one or more thrombophilic traits (there were two patients with protein C deficiency, five with resistance to activated protein C and/or the mutant Factor V Leiden gene, and four with high anticardiolipin antibodies). The 10 patients who were thrombophilic were treated with Coumadin (the international normalized ratio was targeted to 2.5-3.0) for 22 +/- 9 weeks. By self-reported pain-relief numeric rating scores, 6 of the 10 patients with thrombophilia (60%) had > or = 40% pain relief, 2 (20%) had no change, and 2 (20%) had increased pain (30% and 80% worse). Nine of the 10 patients with thrombophilia (90%) had no Coumadin-related side effects; 1 patient (10%) stopped Coumadin therapy (after 28 weeks) because of nosebleeds. Winstrol (6 mg per day) was used for 16 +/- 9 weeks in 20 patients with hypofibrinolysis, some of whom had one or more hypofibrinolytic traits (10 had high levels of plasminogen activator/inhibitor activity, usually accompanied by low stimulated tissue plasminogen activator activity; 13 had high Lp[a] lipoprotein). Of these 20 patients with hypofibrinolysis, 9 patients (45%) had > or = 40% pain relief, 3 patients (15%) had 20% to 30% relief, 5 patients (25%) had no improvement, and 3 patients (15%) had increased pain (30% worse, 60% worse, and 70% worse). Six of the 20 patients with hypofibrinolysis (30%) had no Winstrol-related side effects, while 14 (70%) had side effects that could be attributed to Winstrol, including weight gain, peripheral edema, increased facial and body hair, and acne--all of which were reversed within 6 weeks of stopping Winstrol therapy.
  
  
  CONCLUSIONS
  We postulate that thrombophilia and hypofibrinolysis lead to impaired venous circulation and venous hypertension of the mandible/maxilla with subsequent development of osteonecrosis and chronic facial pain. In many patients, facial pain can be ameliorated by treating the pathogenetic coagulation defects with Coumadin or Winstrol. Large, double-blind, placebo-controlled crossover studies will be required in the future to validate these preliminary results and to determine whether pain relief with Coumadin or Winstrol justifies the risks and side effects associated with these medications, especially for long-term use, in osteonecrosis of the jaws.
authors.affiliation: Cincinnati Jewish Hospital, Cholesterol Center, Ohio, USA.
authors.forename: C J
authors.initials: CJ
authors.lastname: Glueck
authors.forename: R E
authors.initials: RE
authors.lastname: McMahon
authors.forename: J E
authors.initials: JE
authors.lastname: Bouquot
authors.forename: T
authors.initials: T
authors.lastname: Tracy
authors.forename: L
authors.initials: L
authors.lastname: Sieve-Smith
authors.forename: P
authors.initials: P
authors.lastname: Wang
mesh_terms: D000328:Adult; D000368:Aged; D045930:Anabolic Agents / Q000627:therapeutic use; D000925:Anticoagulants / Q000627:therapeutic use; D001778:Blood Coagulation Disorders / Q000150:complications / Q000188:drug therapy*; D005157:Facial Pain / Q000097:blood / Q000188:drug therapy / Q000209:etiology*; D005260:Female; D005342:Fibrinolysis; D006801:Humans; D007571:Jaw Diseases / Q000097:blood / Q000188:drug therapy / Q000209:etiology*; D008297:Male; D008875:Middle Aged; D010020:Osteonecrosis / Q000097:blood / Q000188:drug therapy / Q000209:etiology*; D010865:Pilot Projects; D013197:Stanozolol / Q000627:therapeutic use; D019851:Thrombophilia / Q000150:complications / Q000188:drug therapy*; D014859:Warfarin / Q000627:therapeutic use
chemical_list: D045930:Anabolic Agents; D000925:Anticoagulants; D013197:Stanozolol; D014859:Warfarin